Brokerages predict that Assembly Biosciences (NASDAQ:ASMB) will report sales of $1.88 million for the current quarter, Zacks reports. Two analysts have made estimates for Assembly Biosciences’ earnings. The highest sales estimate is $2.50 million and the lowest is $1.25 million. Assembly Biosciences reported sales of $680,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 176.5%. The company is scheduled to announce its next earnings results on Monday, May 14th.
On average, analysts expect that Assembly Biosciences will report full-year sales of $1.88 million for the current fiscal year, with estimates ranging from $5.00 million to $10.00 million. For the next financial year, analysts forecast that the firm will report sales of $26.33 million per share, with estimates ranging from $5.00 million to $63.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Assembly Biosciences.
ASMB has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 23rd. B. Riley initiated coverage on Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 target price on the stock. Jefferies Group increased their target price on Assembly Biosciences to $75.00 and gave the company a “buy” rating in a research report on Thursday, March 8th. Finally, ValuEngine upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $54.25.
In related news, Director William R. Ringo sold 1,000 shares of the stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $56.37, for a total value of $56,370.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 3,000 shares of company stock valued at $152,550. 19.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jennison Associates LLC raised its stake in Assembly Biosciences by 19.6% in the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after purchasing an additional 347,025 shares during the last quarter. BlackRock Inc. raised its stake in Assembly Biosciences by 19.6% in the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock valued at $48,784,000 after purchasing an additional 176,976 shares during the last quarter. Perceptive Advisors LLC raised its stake in Assembly Biosciences by 21.5% in the 4th quarter. Perceptive Advisors LLC now owns 536,626 shares of the biopharmaceutical company’s stock valued at $24,282,000 after purchasing an additional 94,793 shares during the last quarter. Rock Springs Capital Management LP raised its stake in Assembly Biosciences by 15.4% in the 4th quarter. Rock Springs Capital Management LP now owns 450,000 shares of the biopharmaceutical company’s stock valued at $20,363,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Farallon Capital Management LLC acquired a new position in Assembly Biosciences in the 4th quarter valued at $11,313,000. 76.81% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:ASMB traded up $1.28 during midday trading on Wednesday, reaching $45.89. 85,544 shares of the company’s stock traded hands, compared to its average volume of 177,625. Assembly Biosciences has a 1 year low of $18.60 and a 1 year high of $67.36. The firm has a market capitalization of $903.41, a price-to-earnings ratio of -17.95 and a beta of 0.74.
COPYRIGHT VIOLATION WARNING: “$1.88 Million in Sales Expected for Assembly Biosciences (ASMB) This Quarter” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/04/16/1-88-million-in-sales-expected-for-assembly-biosciences-asmb-this-quarter.html.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.